April 15, 2016
Three separate studies in patients with advanced stages of cancer investigate how blood tests can be used to select patients for therapy will be presented by Biodesix’ scientists and their collaborators at the AACR Annual Meeting in New Orleans.
One study, presented in collaboration with Dr. Jeffrey ... Read more
April 4, 2016
VeriStrat®, Biodesix’ proteomic blood test for patients with advanced NSCLC, has received multiple positive coverage decisions in 2016. As a result, 200 million Americans now have insurance coverage for VeriStrat. The most recent positive coverage decisions include BlueCross BlueShield (BCBS) of Florida and Health Care Services ... Read more
March 9, 2016
Chief Technology Officer for Biodesix, Inc., Dr. Heinrich Roder, will present the company’s approach and recent results for a blood test stratifying patients for immunotherapy benefit on Thursday, March 10, at Molecular Med Tri-Conference.
By modifying ideas from the field of deep learning, Biodesix® can design clinically useful tests from multivariate data ... Read more
March 2, 2016
Norgen Biotek Corp., an innovative Canadian biotechnology company focusing on advancing powerful tools for DNA, RNA and protein stabilization and purification, today announced the signing of a supplier agreement with Biodesix, Inc. to supply novel sample preparation products based on Norgen Biotek’s proprietary purification technology. Biodesix, Inc. is a U.S.-based company ... Read more
February 24, 2016
Biodesix, Inc., a molecular diagnostics company that discovers, develops and commercializes blood tests to deliver personalized medicine in oncology, announced today that the company raised $22 million through the sale of series F preferred stock and other securities. This amount includes capital previously raised through convertible debt and converted into equity ... Read more
February 11, 2016
Biodesix, Inc. today announced that its Chief Executive Officer, David Brunel, is scheduled to present a corporate overview on “Deep Phenotyping, Machine Learning to Precision Medicine” during the Leerink Partners 5th Annual Global Healthcare Conference at the Waldorf Astoria, New York, from February 10-11, 2016. Biodesix’ presentation is scheduled for February ... Read more
January 7, 2016 GeneStrat blood-based mutation testing for advanced lung cancer offers significant advantages for patients and their treating physicians over standard tissue testing, which can delay treatment and increase patient risk due to complications from an invasive biopsy.
November 6, 2015
BOSTON– AACR-NCI-EORTC – November 6, 2015—Biodesix, Inc., today announced that its data on genomic and proteomic blood-based diagnostic assays will be presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. These blood-based diagnostic tests for patients with non-small cell lung cancer (NSCLC) are developed with ... Read more
November 3, 2015
Biodesix, Inc. today announced new clinical findings showing that its novel investigational test, BDX008, based on profiling serum proteins, identifies patients with advanced melanoma who are more likely to have longer progression-free and overall survival with nivolumab therapy. Early data suggesting the test’s clinical potential for guiding anti-PD-1 therapy is being ... Read more
September 7, 2015
Biodesix, Inc. today announced new data regarding VeriStrat®, a serum proteomic test, and epidermal growth factor receptor mutation status in a Phase 1B/2 study of cabozantinib +/- erlotinib in advanced non-small cell lung cancer that is being presented at the World Conference on Lung Cancer.
Details of the presentation are as follows:
MINI 08 ... Read more